CAStar Foods Raises Several Hundred Million RMB in Financing with CEC Capital as Exclusive Financial Advisor

Recently, CAStar Foods, a leader in China’s biosynthetic human-derived bioactive protein industry, announced the closing of a Series A+ financing round worth several hundred million RMB. The company’s independently developed A60 bioactive peptide replicates rare core protein fragments found in breast milk, boasting immense potential in the fields of nutritional immunology and health. Proceeds from this financing round will be mainly allocated to advancing the industrialization of the company’s core functional protein/peptide products and their global market expansion.

CEC Capital acted as the exclusive financial advisor to CAStar Foods for this transaction.

Commenting on the transaction, a Partner at CEC Capital, Liao Jieying, stated:

"CAStar Foods is rooted in cutting-edge technologies developed by the Chinese Academy of Sciences and stands as a pioneer in bioactive functional glycoprotein production. Unlike non-bioactive structural proteins, the company’s first product line—lactoferrin—adheres to the philosophy of ‘Inspired by maternal nutrition, dedicated to maternal and infant markets’. It is poised to drive transformative changes across sectors including functional personal care for perinatal women, food supplements and healthcare products, as well as infant health."